检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]北京军区总医院全军皮肤损伤修复研究所,北京100700
出 处:《实用皮肤病学杂志》2015年第3期178-180,共3页Journal of Practical Dermatology
摘 要:目的比较308nm单频准分子光(308 nm monochromatic excimer light,MEL)与窄谱中波紫外线(narrowband ultraviolet B,NB-UVB)治疗面部白癜风的临床疗效。方法选择面部白癜风患者相邻或对称分布的两处白斑分别照射308nm MEL或NB-UVB,每周2次,共照射20次。结果 308nm MEL组复色达2级需要的平均照射次数为(8.6±1.31)次,NBUVB组为(15.8±4.29)次,308 nm MEL组明显少于NB-UVB组,差异有统计学意义(P<0.05)。308 nm MEL组的总有效率为92.13%,显效率为42.70%,NB-UVB组的总有效率为86.52%,显效率为31.46%。308nm MEL组的显效率明显高于NB-UVB组,差异有统计学意义(P<0.05)。两组的总有效率无统计学意义(P>0.05)。两组的主要不良反应均为暂时性红斑和局部水疱,患者均能耐受。结论 308nm EML治疗面部白癜风比NB-UVB疗效更好,复色更快,但不良反应相似。Objective To compare the efifcacy of 308nm monochromatic excimer light (MEL) and narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of facial vitiligo. Methods One lesion in facial vitiligo patient was treated with the 308nm MEL and its jacent or symmetrical lesion was treated with the NB-UVB. Lesions were treated two times a week for a total of 20 sessions. Results 308 nm MEL group obtained score 2 repigmentation required a mean of (8.6±1.31) treatments, while NB-UVB group required more treatments (15.8±4.29) to achieve the same result (P〈0.05). The total effective rate of 308 nm MEL group and NB-UVB group was 92.13%and 86.52%respectively, with no signiifcant difference (P〉0.05). Of these lesions, 42.70%treated with 308 nm MEL and 31.46%treated with NB-UVB achieved an excellent repigmentation, there was signiifcant difference between the two group ( P〈0.05). The adverse reaction was transient erythema and blister, and all patients of the two groups were well tolerant. Conclusion 308 nm MEL is more effective than NB-UVB in treating facial vitiligo and it induces repigmentation more rapidly, the adverse reaction is similar.
关 键 词:白癜风 面部 308 nm准分子光 窄谱中波紫外线
分 类 号:R758.41[医药卫生—皮肤病学与性病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.26